News

Sarepta Therapeutics Posts Positive Results in Duchenne Muscular Dystrophy Study

May 19, 2021 (Investorideas.com Newswire) Sarepta Therapeutics shares traded 8% higher after the company reported its investigational gene therapy SRP-9001, used for treating Duchenne’s Muscular Dystrophy, had “positive 12-week expression and safety results.”

What's your reaction?

Excited
0
Happy
0
In Love
0
Not Sure
0
Silly
0

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in:News